In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

iCAD adds Hologic compatibility

This article was originally published in The Gray Sheet

Executive Summary

iCAD gains PMA supplement approval for use of its Second Look digital computer-aided detection software with Hologic's Selenia full-field digital mammography (FFDM) system. The approval brings iCAD even with competitor R2 as a provider of CAD for all FDA-approved FFDM systems, including those offered by Hologic, Siemens, GE Healthcare and Fisher...

You may also be interested in...



Hologic teams with iCAD

Firms target low-volume, film-based mammography clinics under a private label distribution pact in which iCAD will make film-based computer-aided detection (CAD) systems for Hologic to combine with its film-based, analog mammography systems. Hologic estimates that lower-volume centers account for over half the market for breast cancer analog CAD products. In September, iCAD gained PMA supplement approval to use its Second Look Digital CAD software with Hologic's Selenia full-field digital mammography system (1"The Gray Sheet" Sept. 20, 2004, In Brief)...

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel